Tweet
The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia
Elena Tsourdi M.D., Ph.D.a, Anargyros Kourtis M.D., Ph.D., a, , Dimitrios Farmakiotis M.D.a, Ilias Katsikis M.D., Ph.D.a, Marios Salmas M.D.a and Dimitrios Panidis M.D., Ph.D.a
aDivision of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
Received 17 February 2008; revised 1 June 2008; accepted 3 June 2008. Available online 9 August 2008.
This study evaluates, compares, and contrasts the effects of three selective estrogen receptor modulators (SERMs), namely, tamoxifen, toremifene, and raloxifene, on the hypothalamic-pituitary-testicular axis in 284 consecutive subfertile men with idiopathic oligozoospermia using three therapeutic protocols: [1] tamoxifen, 20 mg, once daily (n = 94); [2] toremifene, 60 mg, once daily (n = 99); and [3] raloxifene, 60 mg, once daily (n = 91). The antiestrogenic effects of SERMs at the hypothalamic level result in a statistically significant increase of gonadotropin levels, which is more marked for tamoxifen and toremifene compared with raloxifene.
My notes:
Table1 in this study outlines that nolva and torimefene (tor) are statistically significant more effective than raloxifene. nolva does a little bit better than tor wrt to LH level, and tor better than nolva wrt to FSH levels though the difference is not significant. Both do about the same in subjects wrt to T levels.
-----------------------------------------------------------------------------
Hormonal Treatment of Male Review
Infertility: Promises and Pitfalls
DAMA MADHUKAR AND SINGH RAJENDER
From the Central Drug Research Institute, Lucknow, India.
ABSTRACT: Approximately 50% of infertility issues are attributable
to male factors. A number of different factors may result in
similar reductions of sperm count or motility and affect sperm
morphology. Not only is the etiology of male infertility difficult to
understand, but it is equally challenging to treat male infertility
because of its etiological heterogeneity. Because of complex and
incomplete knowledge of the underlying causes, most infertile men
are described as idiopathically oligozoospermic and/or asthenozoospermic.
Different hormonal treatments have been attempted, aiming
to improve mainly endogenous follicle-stimulating hormone and/or
androgen levels and subsequent spermatogenesis. Various studies
have tried to treat infertility through natural pregnancies or increased
sperm retrieval for in vitro fertilization techniques, or by treating spermatozoa
in vitro to improve its fertilizing potential. The present review focuses on all of
the aspects of male infertility treatment by hormone supplementation.
My notes:
This is a review paper on different modalities with an emphasis on nolva, clomid, HcG, HMG, and others. It is insightful and a good read. I would post the article, however, it is in violation of copyright laws. Anyone may access this article at a public/state hospital with internet access for the public (usually in the library). Search the title in PubMed and you should be able to read it in detail.
Elena Tsourdi M.D., Ph.D.a, Anargyros Kourtis M.D., Ph.D., a, , Dimitrios Farmakiotis M.D.a, Ilias Katsikis M.D., Ph.D.a, Marios Salmas M.D.a and Dimitrios Panidis M.D., Ph.D.a
aDivision of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece
Received 17 February 2008; revised 1 June 2008; accepted 3 June 2008. Available online 9 August 2008.
This study evaluates, compares, and contrasts the effects of three selective estrogen receptor modulators (SERMs), namely, tamoxifen, toremifene, and raloxifene, on the hypothalamic-pituitary-testicular axis in 284 consecutive subfertile men with idiopathic oligozoospermia using three therapeutic protocols: [1] tamoxifen, 20 mg, once daily (n = 94); [2] toremifene, 60 mg, once daily (n = 99); and [3] raloxifene, 60 mg, once daily (n = 91). The antiestrogenic effects of SERMs at the hypothalamic level result in a statistically significant increase of gonadotropin levels, which is more marked for tamoxifen and toremifene compared with raloxifene.
My notes:
Table1 in this study outlines that nolva and torimefene (tor) are statistically significant more effective than raloxifene. nolva does a little bit better than tor wrt to LH level, and tor better than nolva wrt to FSH levels though the difference is not significant. Both do about the same in subjects wrt to T levels.
-----------------------------------------------------------------------------
Hormonal Treatment of Male Review
Infertility: Promises and Pitfalls
DAMA MADHUKAR AND SINGH RAJENDER
From the Central Drug Research Institute, Lucknow, India.
ABSTRACT: Approximately 50% of infertility issues are attributable
to male factors. A number of different factors may result in
similar reductions of sperm count or motility and affect sperm
morphology. Not only is the etiology of male infertility difficult to
understand, but it is equally challenging to treat male infertility
because of its etiological heterogeneity. Because of complex and
incomplete knowledge of the underlying causes, most infertile men
are described as idiopathically oligozoospermic and/or asthenozoospermic.
Different hormonal treatments have been attempted, aiming
to improve mainly endogenous follicle-stimulating hormone and/or
androgen levels and subsequent spermatogenesis. Various studies
have tried to treat infertility through natural pregnancies or increased
sperm retrieval for in vitro fertilization techniques, or by treating spermatozoa
in vitro to improve its fertilizing potential. The present review focuses on all of
the aspects of male infertility treatment by hormone supplementation.
My notes:
This is a review paper on different modalities with an emphasis on nolva, clomid, HcG, HMG, and others. It is insightful and a good read. I would post the article, however, it is in violation of copyright laws. Anyone may access this article at a public/state hospital with internet access for the public (usually in the library). Search the title in PubMed and you should be able to read it in detail.
Comment